Serplulimab

Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer[1][2].

Product Specifications

CAS Number

[2231029-82-4]

Product Name Alternative

HLX 10

UNSPSC

12352203

Target

Akt; PD-1/PD-L1; STAT

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/serplulimab.html

Purity

99.30

Solubility

H2O

Smiles

[Serplulimab]

Molecular Weight

(144.18 kDa)

References & Citations

[1]Lee A. Serplulimab: First Approval. Drugs. 2022 Jul;82 (10) :1137-1141.|[2]Zhang Y, et al. Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies. MAbs. 2024 Jan-Dec;16 (1) :2419838.